advertisement
 |
|
|
 |
SPECIAL EDITION
Day 5 at ACHEMA
ACHEMA is known as the world forum for chemical engineering and the process industry. As movers and shakers gather at Frankfurt am Main from 11–15 June to showcase their innovative technologies, new developments, products, and services, the editors of Pharmaceutical Technology Europe bring you updates from the exhibition floor in this special edition of show daily e-newsletters.
|
|
|
|
|
|
Subscribe Subscribers can enjoy each full issue of PharmTech Europe in print, or via PharmTech Europe apps.
subscription offers
|
|
|
|
|
ACHEMA NEWS
The mechanical process technology company will exhibit its technological and consulting services for solid-liquid filtration applications at Achema 2018.
/ read more /
Bosch Packaging Technology will introduce its newest R&D device for continuous oral solid dosage production at Achema 2018.
/ read more /
Coperion will be presenting a new, innovative pneumatic conveying process for plastic pellets that consumes up to 35% less power and generates up to 98% less dust at Achema 2018. Fluidlift ecoblue enables manufacturers of plastic granulates to increase product quality while reducing specific power consumption.
/ read more /
Bowe Systec has developed a modular stand-alone solution specifically designed to meet serialization requirements and that combines all the necessary functions in a single system. The new serialization solution will make its debut at Achema 2018.
/ read more /
|
|
|
FOCUS ON FORMULATION
Choice of carrier can have a significant impact on the capsule filling process as well as the performance of the DPI formulation.
/ read more /
Aston Particle Technologies has developed a technology that produces functionalized particles in a one-step, environmentally friendly process.
/ read more /
Abuse-deterrent opioid formulations generally fall into two categories: the first is based on a physiochemical abuse-deterrent approach and the second combines the opioid with an antagonist.
/ read more /
The high viscosity of highly concentrated monoclonal antibody formulations not only presents processing and storage difficulties, but also formulation and delivery challenges.
/ read more /
|
|
|
advertisement
 |
|
|
|
|
